Duey Marc 4

What Happened

• Marc Duey, a director of Aprea Therapeutics (APRE), was awarded a total of 15,690 restricted stock units (RSUs) on June 16, 2026. The grant is recorded as two items: 3,135 shares and 12,555 derivative shares, each at $0.00 (no cash purchase).

Key Details

• Transaction date: June 16, 2026; Form 4 filed June 17, 2026 (timely filing).
• Grant amounts: 3,135 shares and 12,555 RSUs — total 15,690 RSUs; grant price shown as $0.00 (compensation award).
• Vesting/settlement: These RSUs vest and will be settled into common stock on June 16, 2027, contingent on continued board service and subject to certain acceleration provisions (Footnote F1).
• Beneficial ownership: The reporting person disclaims beneficial ownership of these securities (Footnote F2).
• Post-transaction holdings: The filing does not specify the total shares owned after the grant.
• Note: The filing shows no cash purchase or sale; this is a compensation award rather than a market transaction.

Context

• RSUs are a form of equity compensation: they convert to actual shares only if vesting conditions are met. Because these units are grants tied to service, they reflect company compensation practices rather than an outright “buy” or “sell” signal by the insider.
• No option exercise, sale, or 10b5-1 plan was reported in this filing.